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1. Introduction 
 
In a previous contribution, I showed how the evidence for the 
existence of a CRISPR-based adaptive immunity in 
prokaryotes has been the result of a long and tortuous 
historical process (Morange 2015). After 2007, it was 
admitted that Clustered Regularly Interspaced Short 
Palindromic Repeat (CRISPR) loci harbour spacer sequences 
derived from phages and plasmids. These loci are transcribed, 
and the mRNA is matured into short crRNAs that guide the 
inactivation of phages and plasmids bearing sequences 
identical to those present in the spacers. The CRISPR loci are 
flanked by an ensemble of Cas genes involved in the immune 
response.   
I will extend this story by describing how, in a few years, a 
universal genome editing tool emerged from the study of this 
system. This second part of the story was no less complex and 
tortuous than the first. It also involved numerous participants, 
only some of whom have been projected into the limelight. 
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I will successively describe why, in 2009-2010, DNA was 
definitively considered as a possible target of the CRISPR-Cas 
response, and how the years 2011-2012 were crucial for a 
precise understanding of the mechanisms of CRISPR-Cas9 
interference, but also for the conception of a new genome 
editing tool. In a third part, I will emphasize the importance of 
the previous essays on zinc-finger nucleases and Transcription 
Activator-Like Effector Nucleases (TALENs) in generating, at 
the beginning of 2013, the “CRISPR craze” (Pennisi 2013).   
 
2. DNA is the target! 
 
Transcription of the CRISPR repeated sequences and 
maturation of the RNA into short crRNAs guiding the 
inactivation of the invaders were rapidly demonstrated. The 
role of the Cas proteins in the process was also obvious, 
although the diversity of these proteins in the different 
organisms obscured the precise role of each of them. But how 
did these guide crRNAs interfere with the development of 
phages? Did they interact with the phage DNA, or with its 
RNA transcripts? 
The initially preferred target was RNA. The first reason was 
the parallel between the immunity provided by the CRISPR-
Cas system and the RNA interference response recently 
evidenced in eukaryotes. This parallel, publicized by Koonin 
(Makarova et al. 2006), was present in the minds of all 
experimenters. But there probably was a second reason to 
favour RNA over DNA. The possibility for a small RNA to 
interact with DNA had been often anticipated, but each time 
the hope had vanished: bacterial repressors were not RNAs, 
but proteins; antisense RNAs were efficient at the level of 
translation, not at the level of transcription. The choice of 
RNA as the target resulted also from the direct demonstration 
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in an in vitro system of an “RNA-guided RNA cleavage by a 
CRISPR RNA-Cas protein complex” (Hale et al. 2009, 945). 
But three repeated observations directly supported the 
hypothesis that the target was, at least in certain systems, 
DNA: the fact that antisense sequences were as active as sense 
sequences in interference (Barrangou et al. 2007; Brouns et al. 
2006); the observation that sequences of the invaders can be 
the target of the interference response even if they are not 
present in RNAs – a result shown very elegantly by the use of 
a self-splicing intron (Marraffani and Sontheimer 2008); and 
the evidence that fragments of phage genomes, corresponding 
to genes expressed late during infection, were as efficient in 
protecting as sequences expressed early during infection. 
Taking into account these hard facts, a series of reviews 
written in 2009-2010 supported the hypothesis that the target 
of the crRNAs could be DNA (Waters and Storz 2009; van der 
Oost et al. 2009; Marraffini and Sontheimer 2010). Even 
though Deveau et al. and Philippe Horvath and Rodolphe 
Barrangou preferred to remain cautious in their two reviews 
(2010), given the diversity of CRISPR-Cas systems in bacteria 
and archaea, at the end of the same year both supported the 
hypothesis that plasmid and bacteriophage double-stranded 
DNA were specifically cleaved during interference (Garneau 
et al. 2010; Bhaya et al. 2011), a result confirmed in vitro two 
years later (Gasiunas et al. 2012). 
 
3. The crucial years 2011-2012 
 
In March 2011, Emmanuelle Charpentier and her collaborators 
demonstrated in Streptococcus pyogenes the existence of a 
hitherto unobserved step in the maturation of the crRNAs: the 
participation of a trans-encoded small RNA, tracrRNA with a 
24-nucleotide sequence complementary to the repeat regions 
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of crRNA precursor transcripts (Deltcheva et al. 2011). The 
endogenous bacterial RNAse III was required for immunity, 
presumably because of its participation in the maturation of 
the crRNA – tracrRNA – Csn1 (Cas) complex.  
A little more than one year later, a new publication by the 
same group demonstrated the DNAse activity of an in vitro 
system containing these two RNAS, the Csn1 protein 
rebaptized Cas 9, and a target DNA (Jinek et al. 2012). The 
precise point of DNA cleavage was determined and it was 
shown that two different domains of Cas 9 are involved in the 
cleavage of the two strands of DNA. It was demonstrated that 
the tracrRNA – crRNA – Cas9 complex is required for DNA 
targeting, and the precise interactions between this complex 
and the DNA target were determined. In addition, the paper 
described how the two RNAs could be positioned on one 
unique chimeric RNA guide molecule, making the system 
very easy to use. The demonstration that the system could be 
used to target any DNA sequence was provided by the 
construction of a chimeric RNA molecule guide able to target 
the GFP gene. 
Despite the apparent continuity, there are two huge differences 
between the two papers. The first is centred around the 
process of RNA maturation, and the participation of Cas 
proteins in it. There are no discussions of what might be the 
target of the maturation complex, the mechanisms being “yet 
to be fully understood” (Deltcheva et al. 2011, 602). But the 
description that was provided drew a strong parallel between 
the eukaryotic interfering system acting on RNA and the 
CRISPR-Cas system, between the role of Dicer and of RNAse 
III, a point that did not escape the attention of commentators 
(Gottesman 2011). One year later, all the attention was 
focused on the activity of the Cas9 nuclease, and its control by 
the two small RNAs that were now considered as partners in a 
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“dual-RNA-guided DNA endonuclease” (Jinek et al. 2012, 
816). The role of Csn1 (Cas9) had dramatically changed 
between the two studies. 
There is a second major difference between the two articles. 
The system is now seen as a new potential tool for genome 
editing, superior to the pre-existing zinc fingers and TALE 
nucleases painfully constructed in previous years. In contrast 
to these systems, the same protein (nuclease) can be used in all 
experiments, the single (and easy) necessary change being in 
the sequence of the guide RNA. In addition, the specificity 
provided by the interaction between two oligonucleotide 
sequences was expected to outcompete that reached by an 
interaction between a protein and a nucleic acid. 
What may have occurred between these two articles to explain 
this dramatic reinterpretation of the data, and reorientation of 
the work? The reader is not helped by the 2012 article, written 
within the new framework, and totally silent on what justified 
this reorientation. A review article published in Nature at the 
beginning of 2012 is often cited as a turning point 
(Wiendenheft et al. 2012). Its content does not justify such a 
privileged treatment. It is a bad habit on the part of scientists 
to cite the most recent reviews on a topic, without reading 
them! 
So I can only hypothesize. One paper, briefly mentioned in the 
2012 publication, appears to have been essential: published in 
August 2011 (Sapranauskas et al. 2011), it demonstrated, by 
the transfer of the CRISPr-Cas type II system of Streptococcus 
thermophilus into E. coli, that the Cas9 gene is the only Cas 
gene necessary in this system for interference, and initiated an 
analysis of the functions of the different domains of the 
protein encoded by this gene. This article is fundamental since 
it gave Csn1 (Cas 9) a radically new function in comparison 
with the 2011 article of Emmanuelle Charpentier’s group, and 
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strongly suggested that it directly exerted its nuclease activity 
on DNA.  
The second important contribution was a review written by 
most of the experts in the field, consisting in classifying the 
different CRISPR-Cas systems (Makarova et al. 2011). In this 
review, the description of crRNA and tracrRNA was presented 
in parallel with observations on the essential role of Cas9 and 
the evidence for a DNA cleavage. Preparation of this review 
paper was probably facilitated the rapid circulation of 
information between those involved.    
 
4. From gene targeting to genome editing 
 
The “CRISPR craze” would not have been possible without 
the progressive transformation of another, fully independent 
field of research: the search for tools to inactivate targeted 
genes, to add new genes, and to replace genes by altered 
copies of them. These different objectives do not theoretically 
require the same tools. Cutting the DNA at a precise position 
is not required for the production of genetically modified 
organisms in which the foreign fragments of DNA are inserted 
at any position in the genome. In the production of knockout 
or knockin transgenic mice, in which an altered copy replaces 
the normal copy of a gene, cutting DNA is also not necessary: 
what is done is simply to select the rare embryonic stem cell 
clones where homologous recombination has occurred. 
But both strategies raise huge issues when applied to humans. 
For instance, the insertion of a transgene can occur close to an 
oncogene, and provoke a malignant disease in the recipient 
organism. The idea progressively emerged that the only safe 
strategy to orient the insertion of a transgene or to increase the 
efficiency of substitution was to cut DNA at the position 
where the insertion or the substitution had to occur, in order to 
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increase the efficiency of the repair process by homologous 
and non-homologous recombination. 
The first enzymes selected as candidates were restriction 
enzymes (homing meganucleases), which cut at very specific 
positions in the genome (Jacquier and Dujon 1985). This 
approach became fully efficient with the coupling of a 
nuclease with zinc-finger recognition motifs in which the rules 
of recognition of the targeted nucleotides are simple. Zinc-
finger coupled nucleases were the first demonstrated to be 
efficient for human therapeutic applications, through the 
inactivation of the gene encoding the HIV receptor (Perez et 
al. 2008; Carroll 2008). This success was hugely important in 
raising the visibility of this new experimental approach. It was 
immediately followed by the announcement of even better 
results obtained with TALENs (Christian et al. 2010; Miller et 
al. 2011). It led the authors of these studies to promote the 
replacement of the expression “gene targeting” by “genome 
editing” to emphasize the precision of these new tools (Urnov 
et al. 2010).  
The rapid development of these tools at the end of the 2000s 
had prepared the ground for the CRISPR revolution. The term 
of editing was immediately adopted, and the superiority of the 
CRISPR-Cas9 system was easily demonstrated (Jinek et al. 
2012). 
 
5. Conclusion 
 
A series of papers was published at the beginning of 2013 
demonstrating the potential of the CRISPR-Cas9 editing 
system in bacteria, mouse and human cells, as well as in 
zebrafish. The most remarkable was the efficiency of the 
process, and the possibility of “multiplex” targeting (Cong et 
al. 2013; Mali et al. 2013; Hwang et al. 2013; Cho et al. 2013; 
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Jiang et al. 2013). Homologous recombination can be 
favoured by inactivating one of the two active sites of Cas9, 
now nicking DNA instead of cutting it (Cong et al. 2013). In 
May of the same year, Rudolf Jaenisch’s group demonstrated 
that the new tools not only efficiently inactivated target genes, 
but also induced the precise replacement of nucleotides in 
targeted genes (Wang et al. 2013). The way was open to 
germline modification. Various reviews transformed this 
complex history into a path to “rewriting a genome” 
(Charpentier and Doudna 2013; Doudna and Charpentier 
2014). 
What emerges from this brief historical sketch is that the 
CRISPR craze was the result of the rapid convergence of two 
projects and lines of research that had been fully distinct: the 
search for a mechanistic understanding of a new immune 
system discovered in prokaryotes and efforts to design 
efficient genome editing tools by the construction of specific 
endonucleases. The encounter was explosive because both 
fields had reached a similar degree of maturation and 
expectation at the same time.  
An additional remark is that these extraordinary results were 
the fruit of a “traditional” way of doing biological research. 
Databases were important for the comparison of sequences 
and “deep sequencing” for the characterization of small 
RNAs, but the breakthrough came from the progressive 
analysis of the components, and the in vitro reconstitution of 
the systems, a strategy used since the early days of 
biochemistry! A result as important as the demonstration that 
interference occurred at the level of DNA was provided by the 
“old” Southern method (Garneau et al. 2010), not by new 
post-genomic ones! 
But certainly the most significant result of this study is that 
many researchers participated in this adventure and 
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contributed to one step or another, and several among them 
contributed both to the first steps and to the most recent 
developments. The 2011 review on the CRISPR-Cas systems, 
which was probably, as we suggested, an important trigger for 
the reorientation of the research, was signed by twelve 
authors. The Nobel Prize Committee is greatly to be pitied if it 
has to select only three names from the long list of 
contributors. The worst thing would be to choose not those 
who contributed the most, but those most gifted at rewriting 
history to their own advantage.  
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